Page 8 - Pharma Sector News Today

The pharmaceutical sector in India is showing strong domestic growth of 7% to 9%, despite flat global growth in the US and Europe, according to pharma expert Kewal Handa. He sees good opportunities for Indian companies in the US, as a significant number of patents are set to expire in the next five years. Biosimilars and the application of artificial intelligence in R&D are expected to be major growth areas, and Handa predicts double-digit growth next year.

Except for Pharma and Realty, all sectors ended in the red. Pharma sector saw huge buying interest on the back of good results announced by Cipla and Dr. Reddy, along with a couple of USFDA approval...

There are reports that PE firms Blackstone and Baring Asia, among others, are in talks with Cipla for buying stakes in the company. If the deal goes through, analysts say it will present a greater expanse for growth for one of Indias leading drug makers

The growing positivity around Lupin is clearly demonstrated in the stock’s performance, which has spiked over 38 percent since the start of April. However, some analysts believe the valuation is a bit stretched.

A delayed monsoon and reduced demand for acute products impacted the industry briefly, but analysts expect the sector to sustain double-digit growth figures for the year.

Nuvama Institutional Equities expects better Q1FY24 results for pharmaceutical companies, with revenue and EBITDA growth predicted to be 16%/30% YoY and 4%/7% QoQ, respectively.

Rickenbacker International Airport in Columbus, Ohio, caters to cargo. It is targeting the medicine, vaccine and biologics business with a new temperature-controlled facility. The post Rickenbacker Airport adds refrigeration for Ohio pharma industry appeared first on FreightWaves.

It’s not as if domestic manufacturing has suddenly become sloppy. A closer look will reveal the strides made by Indian pharma firms as they attempt to break into the complex drugs space, which attracts higher scrutiny.

The biotech firm has dosed a patient in China with its drug INS018_055 to treat the chronic lung disease idiopathic pulmonary fibrosis

Jefferies, which sees a 19% upside potential, says JB Chemicals is one of the fastest-growing domestic pharma company with a dominance in cardiac and gastro therapies